Caplin Point Laboratories (NSE:CAPLIPOINT) Altman Z2-Score: 13.98 (As of Jul. 01, 2026) — Near Median


NSE:CAPLIPOINT Caplin Point Laboratories Ltd NSE:CAPLIPOINT
89 GF Score
Price ₹2,626.00
GF Value ₹2,077.29
Valuation Modestly Overvalued
! 5 Warning Signs
View Full Analysis

What is Caplin Point Laboratories Altman Z2-Score?

Caplin Point Laboratories NSE:CAPLIPOINT +2.66% 89 Altman Z2-Score is 13.98 as of Jul. 01, 2026, which is 2% below its 10-year median of 14.23. GuruFocus rates NSE:CAPLIPOINT with a GF Score™ of 89/100 and a GF Value™ of ₹2,077.29 (Modestly Overvalued). The stock has 5 warning signs investors should review. Among 995 Drug Manufacturers companies, Caplin Point Laboratories ranks better than 93.67% on this metric.

Altman Z2-Score, also known as Z"-Score, is used to predict the likelihood that a non-manufacturing company (excluding property/financial company) will face bankruptcy within a two-year period.

Good Sign:

Caplin Point Laboratories has a Altman Z2-Score of 13.98, indicating it is in Safe Zones. This implies the Altman Z2-Score is strong.

The zones of discrimination were as such:

When Altman Z2-Score <= 1.1, it is in Distress Zones.
When Altman Z2-Score >= 2.6, it is in Safe Zones.
When Altman Z2-Score is between 1.1 and 2.6, it is in Grey Zones.

The historical rank and industry rank for Caplin Point Laboratories's Altman Z2-Score or its related term are showing as below:

NSE:CAPLIPOINT' s Altman Z2-Score Range Over the Past 10 Years
Min: 7.15   Med: 14.23   Max: 16.88
Current: 13.98

During the past 13 years, Caplin Point Laboratories's highest Altman Z2-Score was 16.88. The lowest was 7.15. And the median was 14.23.


Caplin Point Laboratories  (NSE:CAPLIPOINT) Altman Z2-Score Explanation

The original Z-Score model was based on publicly traded manufacturing companies while the Z2-Score, also known as Z"-score can be used for any type of company excluding property/financial companies. Both Z-Score and Z2-Score describes the financial health of a company, and its likelihood of financial distress.

X1: The Working Capital/Total Assets (WC/TA) ratio is a measure of the net liquid assets of the firm relative to the total capitalization. Working capital is defined as the difference between current assets and current liabilities. Ordinarily, a firm experiencing consistent operating losses will have shrinking current assets in relation to total assets. Altman found this one proved to be the most valuable liquidity ratio comparing with the current ratio and the quick ratio. This is however the least significant of the five factors.

X2: Retained Earnings/Total Assets: the RE/TA ratio measures the leverage of a firm. Retained earnings is the account which reports the total amount of reinvested earnings and/or losses of a firm over its entire life. Those firms with high RE, relative to TA, have financed their assets through retention of profits and have not utilized as much debt.

X3, Earnings Before Interest and Taxes/Total Assets (EBIT/TA): This ratio is a measure of the true productivity of the firm's assets, independent of any tax or leverage factors. Since a firm's ultimate existence is based on the earning power of its assets, this ratio appears to be particularly appropriate for studies dealing with corporate failure. This ratio continually outperforms other profitability measures, including cash flow.

X4_2, Net Worth (Total Stockholders Equity - Preferred Stock)/Total Liabilities (NW/TL): it compares a company’s stock net worth with its total liabilities and can be used to assess the extent of its reliance on debt.

Read more about Altman Z2-Score, the original research on Z-Score and the additional research on Z2-Score.


Be Aware

Altman Z2-Score does not apply to financial companies.


Caplin Point Laboratories Altman Z2-Score Related Terms


Caplin Point Laboratories Altman Z2-Score Historical Data

* Premium members only.

The historical data trend for Caplin Point Laboratories's Altman Z2-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Caplin Point Laboratories Altman Z2-Score Chart

Caplin Point Laboratories Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Altman Z2-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 14.73 14.47 14.50 16.88 13.98

Caplin Point Laboratories Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Altman Z2-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 16.88 0.00 16.12 0.00 13.98

NSE:CAPLIPOINT vs ZTS, UTHR: Altman Z2-Score Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Caplin Point Laboratories's Altman Z2-Score, along with its competitors' market caps and Altman Z2-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Caplin Point Laboratories Altman Z2-Score vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Caplin Point Laboratories's Altman Z2-Score distribution charts can be found below:

* The bar in red indicates where Caplin Point Laboratories's Altman Z2-Score falls into.


NSE:CAPLIPOINT
89GF Score
Caplin Point Laboratories Ltd NSE:CAPLIPOINT
Altman Z2-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Caplin Point Laboratories Altman Z2-Score Calculation

Altman Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.

Z2-Score, also known as Z"-Score is the Z-Score for non-manufacturing companies excluding property/financial companies.

Caplin Point Laboratories's Altman Z2-Score for today is calculated with this formula:

Z=6.56*X1+3.26*X2+6.72*X3+1.05*X4_2
=6.56*0.5437+3.26*0+6.72*0.1987+1.05*8.6486
=13.98

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency. GuruFocus does not calculate Altman Z2-Score when X4_2 value is 0.

Trailing Twelve Months (TTM) ended in Mar. 2026:
Total Assets was ₹40,455 Mil.
Total Current Assets was ₹25,857 Mil.
Total Current Liabilities was ₹3,859 Mil.
Retained Earnings was ₹0 Mil.
Pre-Tax Income was 2134.4 + 2038.9 + 2010 + 1844.6 = ₹8,028 Mil.
Interest Expense was -3.6 + -1.8 + -1.6 + -1.8 = ₹-9 Mil.
Total Liabilities was ₹4,147 Mil.

* Note that for stock reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data.

X1=Working Capital/Total Assets
=(Total Current Assets - Total Current Liabilities)/Total Assets
=(25856.6 - 3859.4)/40454.8
=0.5437

X2=Retained Earnings/Total Assets
=0/40454.8
=0

X3=Earnings Before Interest and Taxes/Total Assets
=(Pre-Tax Income - Interest Expense)/Total Assets
=(8027.9 - -8.8)/40454.8
=0.1987

X4_2=Net Worth/Total Liabilities
=(Total Stockholders Equity - Preferred Stock)/Total Liabilities
=(35864.2 - 0)/4146.8
=8.6486

The zones of discrimination were as such:

Distress Zones - 1.1 < Grey Zones < 2.6 - Safe Zones

Caplin Point Laboratories has a Altman Z2-Score of 13.98 indicating it is in Safe Zones.

Frequently Asked Questions Learn more about Altman Z2-Score →
What does a Altman Z2-Score of 13.98 mean?
Caplin Point Laboratories (NSE:CAPLIPOINT) has a Altman Z2-Score of 13.98 as of Jul. 01, 2026. Z2-Score is the Z-Score for non-manufacturing companies excluding property/financial companies, which measures a company's bankruptcy risk. View historical data on Caplin Point Laboratories and its competitors. This is near median its historical median of 14.23. Over the past decade, Caplin Point Laboratories' Altman Z2-Score has ranged from 7.15 to 16.88. According to the industry distribution chart, Caplin Point Laboratories ranks #63 out of 995 companies in the Drug Manufacturers industry, placing it in the top 6.3%.
Is Caplin Point Laboratories' Altman Z2-Score too high?
Caplin Point Laboratories' current Altman Z2-Score of 13.98 is near median its 10-year median of 14.23. Over the past 10 years, this metric has ranged from a low of 7.15 to a high of 16.88. The Drug Manufacturers industry median Altman Z2-Score is 3.87. Caplin Point Laboratories' value of 13.98 is 261.2% above this industry median. Based on the distribution chart, Caplin Point Laboratories ranks #63 out of 995 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Caplin Point Laboratories has a GF Score™ of 89/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Caplin Point Laboratories' Altman Z2-Score compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Caplin Point Laboratories ranks #63 out of 995 companies for Altman Z2-Score. This places Caplin Point Laboratories in the top 6% of its industry — outperforming the majority of peers. The industry median Altman Z2-Score is 3.87. Caplin Point Laboratories' value of 13.98 is 261.2% above this benchmark. Historically, Caplin Point Laboratories' own Altman Z2-Score has ranged from 7.15 to 16.88 over the past decade. While the company's 10-year median is 14.23 vs. the industry median of 3.87, Caplin Point Laboratories has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Altman Z2-Score for a Drug Manufacturers company?
The median Altman Z2-Score among Drug Manufacturers companies is 3.87, based on 995 companies in the industry. Companies in the top quartile (top 25%) have a Altman Z2-Score significantly above this median, while those in the bottom quartile fall well below. However, Altman Z2-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Caplin Point Laboratories's current Altman Z2-Score of 13.98 is 261.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Altman Z2-Score mean?
A high Altman Z2-Score can signal that a stock is expensive relative to its fundamentals. Z2-Score is the Z-Score for non-manufacturing companies excluding property/financial companies, which measures a company's bankruptcy risk. View historical data on Caplin Point Laboratories and its competitors. For the Drug Manufacturers industry, the median Altman Z2-Score is 3.87 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Caplin Point Laboratories's current Altman Z2-Score is 13.98, which is near median its own 10-year median of 14.23. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Caplin Point Laboratories stock overvalued right now?
Based on GuruFocus' analysis, Caplin Point Laboratories (NSE:CAPLIPOINT) is currently considered Modestly Overvalued. The stock's GF Value™ is ₹2,077.29, compared to a current price of ₹2,626.00 — trading 26.4% above its estimated fair value. The current Altman Z2-Score is 13.98, which is near median its 10-year median of 14.23 and 261.2% above the Drug Manufacturers industry median of 3.87. Caplin Point Laboratories' overall GF Score™ is 89/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Altman Z2-Score calculated?
Altman Z2-Score is calculated from a company's financial statements. For Caplin Point Laboratories (NSE:CAPLIPOINT), the current Altman Z2-Score is 13.98 as of Jul. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Caplin Point Laboratories (NSE:CAPLIPOINT) Overvalued in 2026?

Based on GuruFocus' analysis, Caplin Point Laboratories stock appears to be overvalued. The current stock price of ₹2,626.00 is trading 26.4% above its estimated GF Value™ of ₹2,077.29. GuruFocus considers Caplin Point Laboratories to be Modestly Overvalued.

Key valuation signals for NSE:CAPLIPOINT:

  • Altman Z2-Score: 13.98 (near median its 10-year median of 14.23)
  • GF Value™: ₹2,077.29 vs. price of ₹2,626.00 (26.4% above fair value)
  • GF Score™: 89/100 with 5 warning signs
  • Industry Position: 261.2% above the Drug Manufacturers median (#63 of 995)

No single metric tells the full story. See the NSE:CAPLIPOINT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Caplin Point Laboratories Business Description

Other Exchanges 524742:India
Address Ashvich Tower, Developed Plots Industrial Estate, No. 3, 3rd Floor, Perungudi, Chennai, TN, IND, 600 096
Caplin Point Laboratories Ltd is an India-based pharmaceutical company. It is engaged in the manufacturing and marketing of pharmaceutical products. The company's key products include tablets, capsules, injections (liquid and lyophilized, prefilled syringes), ophthalmic solutions, liquid orals, soft gel capsules, ointments, creams, gels, powders for injections, suppositories, ovules, pre-mix bag formulations, inhalers, sprays, and IV infusions. It also provides pharmaceutical formulations in specialized injectable dosage forms and Ophthalmic drops.
89GF Score

Get the complete analysis for NSE:CAPLIPOINT

Altman Z2-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹2,626.00
Price
₹2,077.29
GF Value